natgillin/translations-raw huggingface dataset:
The most common adverse reactions (≥ 5% in a Phase 3 trial of hospital-acquired pneumonia, including ventilator-associated pneumonia) occurring in patients receiving Zerbaxa were diarrhoea, alanine aminotransferase increased, and aspartate aminotransferase increased and were generally mild or moderate in severity. 
Najpogostejši neželeni učinki (≥ 5 % v preskušanju 3. faze pri bolnišnični pljučnici, vključno s pljučnico, povezano z umetnim predihavanjem) pri bolnikih, ki so prejemali zdravilo Zerbaxa, so bili diareja, zvišana alanin-aminotransferaza in zvišana aspartat-aminotransferaza ter so bili večinoma blagi ali zmerni.
Zerbaxa is available in packs containing 20 mL Type I clear glass vial with stopper (bromobutyl rubber) and flip-off seal. 
Zdravilo Zerbaxa je na voljo v pakiranjih, ki vsebujejo 20 ml vialo iz prozornega stekla tipa I z zamaškom (brombutilna guma) in snemno zaporko.
62%, respectively and are similar to those in healthy subjects (approximately 61% and 63%, respectively) receiving 1 g / 0.5 g ceftolozane/tazobactam. 
ter podobno kot pri zdravih preiskovancih (približno 61 % oz. 63 %), ki so prejeli 1 g/0,5 g ceftolozana/tazobaktama.
The recommended dose of Zerbaxa is 1 g of ceftolozane and 0.5 g of tazobactam or 2 g of ceftolozane and 1 g of tazobactam every 8 hours, which is given into one of your veins (directly into the bloodstream). 
Priporočeni odmerek zdravila Zerbaxa je 1 g ceftolozana in 0,5 g tazobaktama ali 2 g ceftolozana in 1 g tazobaktama na 8 ur v veno (neposredno v krvni obtok).
*To be used in combination with metronidazole when anaerobic pathogens are suspected. 
*V primeru suma na anaerobne patogene je treba zdravilo uporabiti v kombinaciji z metronidazolom.
The development of a positive direct antiglobulin test (DAGT) may occur during treatment with ceftolozane/tazobactam (see section 4.8). 
Med zdravljenjem s ceftolozanom/tazobaktamom lahko pride do pozitivnega direktnega antiglobulinskega testa (DAGT - direct antiglobulin test) (glejte poglavje 4.8).
**To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process. 
**V primeru, ko je znano oziroma v primeru suma, da grampozitivne bakterije pripomorejo k vnetnim procesom, je treba zdravilo uporabiti v kombinaciji z antibiotikom, ki deluje proti grampozitivnim bakterijam.
For ceftolozane the time that the plasma concentration exceeds the minimum inhibitory concentration of ceftolozane for the infecting organism has been shown to be the best predictor of efficacy in animal models of infection. 
Za ceftolozan se je pokazalo, da je najboljši napovednik njegove učinkovitosti v živalskih modelih okužb čas, v katerem plazemska koncentracija preseže minimalno inhibitorno koncentracijo ceftolozana za organizem, ki je povzročil okužbo.
The highest single dose of Zerbaxa used in clinical trials was 3 g / 1.5 g of ceftolozane/tazobactam administered to healthy volunteers. 
Največji enkratni odmerek zdravila Zerbaxa, uporabljen v kliničnih preskušanjih pri zdravih prostovoljcih, je bil 3 g/1,5 g ceftolozana/tazobaktama.
Infection due to C. difficile bacteria, C. difficile test positive (from stool test), Coombs test positive (a blood test that looks for antibodies that may fight against your red blood cells) 
Občasni neželeni učinki (pojavijo se lahko pri največ 1 od 100 bolnikov): okužba z bakterijo C. difficile, pozitiven izvid za C. difficile (na preiskavi blata), pozitiven Coombsov test (preiskava krvi za odkrivanje protiteles, ki lahko delujejo proti rdečim krvnim celicam)
Dizziness may occur following administration of Zerbaxa (see section 4.8). 
Po uporabi zdravila Zerbaxa se lahko pojavi omotica (glejte poglavje 4.8).
Gram-negative bacteria Enterobacter cloacae Escherichia coli Haemophilus influenzae Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens 
Gramnegativne bakterije Enterobacter cloacae Escherichia coli Haemophilus influenzae Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
When the powder is reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for injection, the vial contains 11.5 mmol (265 mg) of sodium. 
Če se prašek rekonstituira z 10 ml natrijevega klorida 0,9 % (9 mg/ml) raztopino za injiciranje, vsebuje viala 11,5 mmol (265 mg) natrija.
Respiratory, thoracic, and mediastinal disorders 
Bolezni dihal, prsnega koša in mediastinalnega prostora dispneja
Metallo-beta-lactamases (e.g., New Delhi metallo-beta-lactamase [NDM]) iv. Ambler Class D beta-lactamases (OXA-carbapenemases) 
serinskih karbapenemaz (npr. karbapenemaz Klebsiella pneumoniae [KPC]) iii. metalo-betalaktamaz (npr. metalo-betalaktamaze New Delhi [NDM]) iv. betalaktamaz razreda D po Amblerju (OXA-karbapenemaz)
Table 1: Intravenous dose of Zerbaxa by type of infection in patients with creatinine clearance > 50 mL/min 
Preglednica 1: Intravenski odmerek zdravila Zerbaxa glede na vrsto okužbe pri bolnikih z očistkom kreatinina > 50 ml/min
Ceftolozane/tazobactam is also contraindicated in patients with severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g., penicillins or carbapenems) (see section 4.3). 
Kombinacija ceftolozana/tazobaktama je kontraindicirana tudi pri bolnikih s hudo preobčutljivostjo (npr. anafilaktično reakcijo, hudo kožno reakcijo) na katero koli vrsto betalaktamskih antibiotikov (npr. na peniciline ali karbapeneme) (glejte poglavje 4.3).
- The other excipients are sodium chloride, arginine, and citric acid, anhydrous. 
- Druge sestavine zdravila so natrijev klorid, arginin in brezvodna citronska kislina.
The mean (coefficient of variation CV%) steady-state volume of distribution of ceftolozane/tazobactam in healthy adult males (n=51) following a single 1 g / 0.5 g IV dose was 13.5 L (21%) and 18.2 L (25%) for ceftolozane and tazobactam, respectively, similar to extracellular fluid volume. 
Povprečni (koeficient variacije KV %) volumen porazdelitve ceftolozana/tazobaktama v stanju dinamičnega ravnovesja po enkratnem intravenskem odmerku 1 g/0,5 g pri zdravih odraslih moških (n = 51) je bil za ceftolozan 13,5 l (21 %) in za tazobaktam 18,2 l (25 %), kar je podobno volumnu zunajcelične tekočine.
The most common adverse reactions (≥ 3% in pooled Phase 3 trials of complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis) occurring in patients receiving Zerbaxa were nausea, headache, constipation, diarrhoea, and pyrexia and were generally mild or moderate in severity. 
Najpogostejši neželeni učinki (≥ 3 % v združenih preskušanjih 3. faze pri zapletenih okužbah v trebušni votlini in zapletenih okužbah sečil, vključno s pielonefritisom) pri bolnikih, ki so prejemali zdravilo Zerbaxa, so bili navzea, glavobol, zaprtje, diareja in zvišana telesna temperatura ter so bili večinoma blagi ali zmerni.
Ceftolozane and tazobactam were not substrates for P-gp or BCRP, and tazobactam was not a substrate for OCT2, in vitro at therapeutic plasma concentrations. 
Ceftolozan in tazobaktam v terapevtskih plazemskih koncentracijah in vitro nista bila substrata P-gp ali BCRP in tazobaktam ni bil substrat OCT2.
Blood and the lymphatic system disorders 
Bolezni krvi in limfatičnega sistema trombocitoza anemija
The development of a positive direct Coombs test may occur during treatment with Zerbaxa. 
Med zdravljenjem z zdravilom Zerbaxa se lahko pojavi pozitiven izvid direktnega Coombsovega testa.
Ceftolozane/tazobactam contains 230 mg sodium per vial, equivalent to 11.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult. 
Kombinacija ceftolozana/tazobaktama vsebuje 230 mg natrija na vialo, kar ustreza 11,5 % največjega priporočenega dnevnega vnosa (po WHO) 2 g natrija za odrasle.
How to take Zerbaxa 
Kako uporabljati zdravilo Zerbaxa
Ceftolozane/tazobactam is not active against bacteria that produce beta-lactamase enzymes which are not inhibited by tazobactam. 
Kombinacija ceftolozana/tazobaktama ni učinkovita proti bakterijam, ki tvorijo encime betalaktamaze, katerih pa tazobaktam ne zavira.
Ceftolozane, tazobactam and the tazobactam metabolite M1 are eliminated by the kidneys. 
Ceftolozan, tazobaktam in presnovek tazobaktama M1 se izločijo skozi ledvice.
The powder for concentrate for solution for infusion for each vial is reconstituted with 10 mL of water for injections or sodium chloride 9 mg/mL (0.9%) solution for injection per vial; following reconstitution the vial should be shaken gently to dissolve the powder. 
Prašek za koncentrat za raztopino za infundiranje v eni viali je treba rekonstituirati z 10 ml vode za injekcije ali 0,9 % (9 mg/ml) raztopine natrijevega klorida za injiciranje na vialo; po rekonstituciji je treba vialo rahlo pretresti, da se prašek raztopi.
**Based on 2 g ceftolozane / 1 g tazobactam intravenously every 8 hours. 
**Na podlagi 2 g ceftolozana/1 g tazobaktama intravensko na 8 ur.
With haemodialysis, the dose should be administered immediately following completion of dialysis (see section 4.2). 
Pri hemodializi je treba odmerek dati takoj po koncu dialize (glejte poglavje 4.2).
Complicated urinary tract infections, including pyelonephritis 
Zapletene okužbe sečil, vključno s pielonefritisom
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions and would normally not be longer than 24 hours at 2 to 8°C. 
Čas običajno ne sme presegati 24 ur pri temperaturi od 2 do 8 °C, razen če sta rekonstitucija/redčenje opravljena v nadzorovanih in preverjenih aseptičnih pogojih.
In a population pharmacokinetic analysis of ceftolozane/tazobactam, no clinically relevant differences in exposure were observed with regard to age. 
Populacijska farmakokinetična analiza ceftolozana/tazobaktama ni pokazala klinično pomembnih razlik v izpostavljenosti glede na starost.
Hepatic impairment No dose adjustment is necessary in patients with hepatic impairment (see section 5.2). 
Okvara jeter Prilagoditev odmerka pri bolnikih z okvaro jeter ni potrebna (glejte poglavje 5.2).
Gram-negative bacteria Enterobacter cloacae Escherichia coli Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa 
Gramnegativne bakterije Enterobacter cloacae Escherichia coli Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa
Ceftolozane/tazobactam is contraindicated in patients with a history of hypersensitivity to ceftolozane, tazobactam, or cephalosporins (see section 4.3). 
Kombinacija ceftolozana/tazobaktama je kontraindicirana pri bolnikih, ki imajo v anamnezi preobčutljivost na ceftolozan, tazobaktam ali cefalosporine (glejte poglavje 4.3).
Following a single 1-hour intravenous infusion of 2 g / 1 g ceftolozane/tazobactam to critically ill patients with CrCL greater than or equal to 180 mL/min (N=10), mean terminal half-life values of ceftolozane and tazobactam were 2.6 hours and 1.5 hours, respectively. 
Po enkratni 1-urni intravenski infuziji 2 g/1 g ceftolozana/tazobaktama pri kritično bolnih bolnikih z očistkom kreatinina večjim ali enakim 180 ml/min (n = 10) je bil povprečni terminalni razpolovni čas ceftolozana 2,6 ure in tazobaktama 1,5 ure.
No dose adjustment of ceftolozane/tazobactam based on age alone is recommended. 
Prilagoditev odmerka ceftolozana/tazobaktama zgolj zaradi starosti ni potrebna.
As ceftolozane/tazobactam does not undergo hepatic metabolism, the systemic clearance of ceftolozane/tazobactam is not expected to be affected by hepatic impairment. 
Ker se ceftolozan in tazobaktam ne presnavljata v jetrih, ni pričakovati, da bi okvara jeter vplivala na sistemski očistek ceftolozana/tazobaktama.
In clinical studies, there was no evidence of haemolysis in patients who developed a positive direct Coombs test in any treatment group. 
V kliničnih študijah pri bolnikih, pri katerih se je pojavil pozitiven izvid direktnega Coombsovega testa, v nobeni terapevtski skupini niso ugotovili znakov hemolize.
Following 1 hour intravenous infusions of 2 g / 1 g ceftolozane/tazobactam or adjusted based on renal function every 8 hours in ventilated patients with confirmed or suspected pneumonia (N=22), ceftolozane and tazobactam concentrations in pulmonary epithelial lining fluid were greater than 8 mcg/mL and 1 mcg/mL, respectively, over 100% of the dosing interval. 
Po enourni intravenski infuziji 2 g/1 g ceftolozana/tazobaktama (ali prilagojeno delovanju ledvic) na 8 ur pri ventiliranih bolnikih, s potrjeno pljučnico ali sumom nanjo (n = 22), je bila v 100 % odmernega intervala koncentracija ceftolozana v tekočini pljučne epitelijske sluznice večja od 8 mcg/ml in tazobaktama večja od 1 mcg/ml.
The Cmax and AUC of ceftolozane/tazobactam increase approximately in proportion to dose within ceftolozane single-dose range of 250 mg to 3 g and tazobactam single-dose range of 500 mg to 1.5 g. No appreciable accumulation of ceftolozane/tazobactam is observed following multiple 1-hour IV infusions of 1 g / 0.5 g ceftolozane/tazobactam or 2 g / 1 g ceftolozane/tazobactam administered every 8 hours for up to 10 days in healthy adults with normal renal function. 
Cmax in AUC ceftolozana/tazobaktama naraščata približno sorazmerno odmerku v razponu enkratnega odmerka ceftolozana od 250 mg do 3 g in v razponu enkratnega odmerka tazobaktama od 500 mg do 1,5 g. Pri zdravih odraslih z normalnim delovanjem ledvic niso opazili pomembnega kopičenja ceftolozana/tazobaktama po večkratnih 1-urnih intravenskih infuzijah 1 g/0,5 g ceftolozana/tazobaktama ali 2 g/1 g ceftolozana/tazobaktama, uporabljenih na 8 ur do 10 dni.
Ceftolozane administered to rats during pregnancy and lactation was associated with a decrease in auditory startle response in postnatal day (PND) 60 male pups (see section 5.3). 
Uporaba ceftolozana pri podganah med brejostjo in laktacijo je bila pri podganjih mladičih - samcih povezana z zmanjšanjem zdrznitve na slušni dražljaj 60. dan po skotitvi (glejte poglavje 5.3).
Applies across all indications: complicated intra-abdominal infections, acute pyelonephritis, complicated urinary tract infections, and hospital-acquired pneumonia, including ventilator-associated pneumonia. 
Velja za vse indikacije: zapletene okužbe v trebušni votlini, akutni pielonefritis, zapletene okužbe sečil in bolnišnično pljučnico, vključno s pljučnico, povezano z umetnim predihavanjem.
What Zerbaxa contains - The active substances are ceftolozane and tazobactam. 
Kaj vsebuje zdravilo Zerbaxa - Zdravilni učinkovini sta ceftolozan in tazobaktam.
No significant medicinal product interactions are anticipated between ceftolozane/tazobactam and substrates, inhibitors, and inducers of cytochrome P450 enzymes (CYPs) based on in vitro and in vivo studies. 
Med ceftolozanom/tazobaktamom in substrati, zaviralci in induktorji encimov citokroma P450 (CYP) glede na študije in vitro in vivo ni pričakovati pomembnih medsebojnih delovanj z zdravili.
Fertility studies in rats showed no effect on fertility and mating after intraperitoneal administration of tazobactam or intravenous administration of ceftolozane (see section 5.3). 
Študije plodnosti na podganah po intraperitonealni uporabi tazobaktama ali intravenski uporabi ceftolozana niso pokazale vpliva na plodnost in parjenje (glejte poglavje 5.3).
White to yellowish powder. 
bel do rumenkast prašek
Zerbaxa contains sodium 
Zdravilo Zerbaxa vsebuje natrij
500 mg ceftolozane / 250 mg tazobactam intravenously every 8 hours 
500 mg ceftolozana/250 mg tazobaktama intravensko na 8 ur
Sodium chloride, arginine, citric acid, anhydrous 
natrijev klorid, arginin, brezvodna citronska kislina
250 mg ceftolozane / 125 mg tazobactam intravenously every 8 hours 
250 mg ceftolozana/125 mg tazobaktama intravensko na 8 ur
Ceftolozane/tazobactam and the tazobactam metabolite M1 are eliminated by the kidneys. 
Ceftolozan/tazobaktam in presnovek tazobaktama M1 se izločijo skozi ledvice.
In vitro data indicate that ceftolozane did not inhibit P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, MRP, BSEP, OAT1, OAT3, MATE1, or MATE2-K in vitro at therapeutic plasma concentrations. 
Podatki in vitro kažejo, da ceftolozan v terapevtskih plazemskih koncentracijah in vitro ni zavrl P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, MRP, BSEP, OAT1, OAT3, MATE1 ali MATE2-K.
Specific for the hospital-acquired pneumonia, including ventilator-associated pneumonia indication treated with Zerbaxa (2 g / 1 g intravenously every 8 hours) for up to 14 days. 
Značilno za indikacijo bolnišnična pljučnica, vključno s pljučnico, povezano z umetnim predihavanjem, zdravljeno z zdravilom Zerbaxa (2 g/1 g intravensko na 8 ur) do 14 dni.
Hospital-acquired pneumonia, including ventilator-associated pneumonia** *Based on 1 g ceftolozane / 0.5 g tazobactam intravenously every 8 hours. 
H. influenzae bolnišnična pljučnica, vključno s pljučnico, povezano z umetnim predihavanjem** *Na podlagi 1 g ceftolozana/0,5 g tazobaktama intravensko na 8 ur.
The reconstituted vial with 10 mL of 0.9% sodium chloride (normal saline) for injection contains 265 mg sodium per vial, equivalent to 13.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult. 
Viala, pripravljena (rekonstituirana) z 10 ml 0,9 % natrijevega klorida (fiziološke raztopine) za injiciranje, vsebuje 265 mg natrija na vialo, kar ustreza 13,3 % največjega priporočenega dnevnega vnosa (po WHO) 2 g natrija za odrasle.
There are no data on the use of ceftolozane/tazobactam in pregnant women. 
Podatkov o uporabi ceftolozana/tazobaktama pri nosečnicah ni. Tazobaktam prehaja skozi placento.
Mean pulmonary epithelial-to-free plasma AUC ratios of ceftolozane and tazobactam were approximately 50% and 
Povprečno razmerje med AUC v pljučnem epiteliju in AUC proste učinkovine v plazmi je bilo za ceftolozan približno 50 % in za tazobaktam približno 62 %
Clostridioides difficile-associated diarrhoea 
Diareja, povezana s Clostridioides difficile
Headache, stomach ache, constipation, diarrhoea, nausea, vomiting, increase in liver enzymes (from blood tests), rash, fever (high temperature), decrease in blood pressure, decrease in potassium (from blood tests), increase in the number of certain types of blood cells known as platelets, dizziness, anxiety, difficulty sleeping, infusion site reactions 
Bolniki, zdravljeni zaradi zapletenih okužb v trebuhu, ledvicah in drugih delih sečil Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov): glavobol, bolečine v trebuhu, zaprtje, driska, slabost s siljenjem na bruhanje, bruhanje, zvišanje jetrnih encimov (na preiskavah krvi), izpuščaj, zvišana telesna temperatura, znižanje krvnega tlaka, znižanje kalija (na preiskavah krvi), zvečanje števila določene vrste krvnih celic, ki jih imenujemo trombociti, omotica, tesnoba, težave s spanjem, reakcija na mestu infundiranja
Each vial contains ceftolozane sulfate equivalent to 1 g ceftolozane and tazobactam sodium equivalent to 0.5 g tazobactam. 
Ena viala vsebuje ceftolozan sulfat, kolikor ga ustreza 1 g ceftolozana, in natrijev tazobaktamat, kolikor ga ustreza 0,5 g tazobaktama.
Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftolozane/tazobactam. 
Pri bolnikih, pri katerih se med uporabo ceftolozana/tazobaktama ali po njej pojavi diareja, je zato pomembno pomisliti na to diagnozo.
In a population pharmacokinetic analysis of ceftolozane/tazobactam, no clinically relevant differences in AUC were observed for ceftolozane and tazobactam. 
Populacijska farmakokinetična analiza ceftolozana/tazobaktama ni pokazala klinično pomembnih razlik AUC ceftolozana in tazobaktama.
Ischemic stroke 
Okvara ledvic
The recommended dose in complicated intra-abdominal infections, complicated urinary tract infections, and acute pyelonephritis subjects with end stage renal disease on haemodialysis is a single loading dose of 500 mg / 250 mg ceftolozane/tazobactam followed by a 100 mg / 50 mg maintenance dose of ceftolozane/tazobactam administered every 8 hours for the remainder of the treatment period. 
Priporočeni odmerek pri bolnikih z zapletenimi okužbami v trebušni votlini, zapletenimi okužbami sečil ali akutnim pielonefritisom ter s končno odpovedjo ledvic na hemodializi je enkratni polnilni odmerek 500 mg/250 mg ceftolozana/tazobaktama, ki mu sledi vzdrževalni odmerek 100 mg/50 mg ceftolozana/tazobaktama na 8 ur med preostalim obdobjem zdravljenja.
The elimination half-life (t½) of ceftolozane is independent of dose. 
Eliminacijski razpolovni čas (t1/2) ceftolozana ni odvisen od odmerka.
3, increased serum gamma-glutamyl transpeptidase (GGT) 
2, zvišana gamaglutamiltransferaza pozitiven Coombsov test zvišana serumska gama-glutamiltranspeptidaza (GGT)
The mean terminal elimination half-life of ceftolozane and tazobactam in healthy adults with normal renal function is approximately 3 hours and 1 hour, respectively. 
Pri zdravih odraslih z normalnim delovanjem ledvic je povprečni terminalni eliminacijski razpolovni čas ceftolozana 3 ure in tazobaktama 1 uro.
The recommended dose in hospital-acquired pneumonia, including ventilator-associated pneumonia subjects with end stage renal disease on haemodialysis is a single loading dose of 1.5 g / 0.75 g ceftolozane/tazobactam followed by a 300 mg / 150 mg maintenance dose of ceftolozane/tazobactam administered every 8 hours for the remainder of the treatment period. 
Priporočeni odmerek pri bolnikih z bolnišnično pljučnico, vključno s pljučnico, povezano z umetnim predihavanjem, in končno odpovedjo ledvic na hemodializi je enkratni polnilni odmerek 1,5 g/0,75 mg ceftolozana/tazobaktama, ki mu sledi vzdrževalni odmerek 300 mg/150 mg ceftolozana/tazobaktama na 8 ur med preostalim obdobjem zdravljenja.
The reconstituted vial with 10 mL of 0.9% sodium chloride (normal saline) for injection contains 265 mg sodium in each vial. 
Viala, pripravljena (rekonstituirana) z 10 ml 0,9 % natrijevega klorida (fiziološke raztopine) za injiciranje, vsebuje 265 mg natrija na vialo.
1, increased serum alkaline phosphatase Clostridioides test positive 
1, zvišana serumska alkalna fosfataza
If you are breast-feeding, your doctor will advise you on whether you should stop breast-feeding or stop or avoid Zerbaxa therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for you. 
Če dojite, vam bo zdravnik povedal, ali morate prenehati dojiti ali prenehati zdravljenje z zdravilom Zerbaxa oziroma ne smete začeti zdravljenja z zdravilom Zerbaxa.
The incidence of seroconversion to a positive direct Coombs test was 31.2% in patients receiving Zerbaxa and 3.6% in patients receiving meropenem in the hospital-acquired pneumonia, including ventilator-associated pneumonia clinical trial. 
V kliničnem preskušanju pri bolnišnični pljučnici, vključno s pljučnico, povezano z umetnim predihavanjem, je bila pojavnost serokonverzije v pozitiven izvid direktnega Coombsovega testa 31,2 % pri bolnikih, ki so prejemali zdravilo Zerbaxa, in 3,6 % pri bolnikih, ki so prejemali meropenem.
In vitro data indicate that neither tazobactam nor the tazobactam metabolite M1 inhibit P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, or BSEP transporters at therapeutic plasma concentrations. 
Podatki in vitro kažejo, da niti tazobaktam niti njegov presnovek M1 v terapevtskih plazemskih koncentracijah ne zavirata prenašalcev P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2 ali BSEP.
Plasma levels of ceftolozane/tazobactam do not increase appreciably following multiple IV infusions of up to 2.0 g / 1.0 g administered every 8 hours for up to 10 days in healthy adults with normal renal function. 
Koncentracija ceftolozana/tazobaktama v plazmi se pri zdravih odraslih z normalnim delovanjem ledvic po intravenskih infuzijah odmerkov do 2,0 g/1,0 g na 8 ur v obdobju do 10 dni ne poveča opazno.
These enzymes make bacteria resistant to ceftolozane by breaking down the antibiotic before it can act. By blocking their action, tazobactam makes ceftolozane more effective at killing bacteria. 
Ti encimi naredijo bakterije odporne proti ceftolozanu, ker ga razgradijo, preden lahko deluje.